This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock Praxis said on Thursday that it made two submissions earlier this year to the FDA, seeking clearance to market ulixacaltamide for the treatment of essential tremor and relutrigine for the treatment of Developmental and Epileptic Encephalopathy.
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.
Soleus Adds a Significant Number of Celcuity Shares This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year downturn that plagued the market between 2022 and 2024. This resurgence is not merely a product of
Why Praxis Precision Medicines Stock Popped Today A medical breakthrough is shining a light on the biotech's promising development platform.
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a
